+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

“Global Rare Disease Drugs market set to grow to $257bn by 2024” says new Visiongain report

01 August 2019
Pharma

Visiongain has launched a new pharma report Global Rare Disease Drugs Market Report: Oncology, Metabolic Diseases, Neurologic Diseases, Haematology Diseases, Infectious Diseases, Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies.

The global rare disease drugs market is one that is driven by innovation which is vital for maintaining the rich pipeline of rare diseases drugs seen in the market today. There is an increasing focus to identify and treat rare diseases that currently are undertreated which creates a strong platform for both start-ups and larger pharmaceutical companies to create new drugs that are not already on the market.

The lead analyst of the report commented "It is difficult to investigate rare diseases as the pool of patients is very small and often results in inadequate clinical knowledge. As a result, rare diseases lack published data on long-term outcomes of treatment and are often characterized incompletely. This requires exploring international and regional research partnerships, collaborating with doctors working on any rare disease, and with patient groups and families dealing with the consequences of these disorders."

Leading companies featured in the report AbbVie, Bristol-Myers Squibb (BMS), Celgene, Merck & Co., Inc., Novartis, Pfizer, Roche, Sanofi, Takeda, Teva and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Cell & Gene Therapy Cold Chain Logistics Market

The global Cell and Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15.5% by 2034

19 June 2024

Read

Cancer Immunotherapy Market

The global Cancer Immunotherapy market is projected to grow at a CAGR of 12.6% by 2034

11 June 2024

Read

Biological Safety Testing Market

The global Biological Safety Testing market is projected to grow at a CAGR of 12.6% by 2034

11 June 2024

Read

CAR-T Therapy Market

The global CAR-T Therapy market is projected to grow at a CAGR of 35.9% by 2034

11 June 2024

Read